



an Open Access Journal by MDPI

## Breast Cancer: From Pathophysiology to Therapeutic Strategies

Guest Editors:

### Dr. Xuemei Xie

Department of Breast Medical  
Oncology, Division of Cancer  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX, USA

### Dr. Toshiaki Iwase

Department of Breast Medical  
Oncology, Division of Cancer  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX, USA

### Dr. Jangsoon Lee

Department of Breast Medical  
Oncology, Division of Cancer  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX, USA

Deadline for manuscript  
submissions:

**closed (30 June 2023)**

### Message from the Guest Editors

Dear Colleagues,

This Special Issue, “Breast Cancer: From Pathophysiology to Therapeutic Strategies”, will focus on the pathophysiology of breast cancer, new prognostic and/or predictive biomarkers of breast cancer, and novel therapeutic approaches for this disease.

Breast cancer is the most common cancer among women in the United States and around the world. The pathophysiology of breast cancer is complex, and numerous factors in a tumor and its microenvironment coordinately contribute to its progression and aggressiveness. Use of biomarkers has advanced breast cancer diagnosis and prognosis and prediction of therapeutic response. Identification of biomarkers has also advanced the development of targeted therapies for breast cancer. Novel therapeutic approaches and drug delivery systems have shown a promising beneficial effect in preclinical or clinical settings by affecting tumorigenesis, metastasis, and tumor–microenvironment interactions.

This Special Issue invites original articles and reviews on the topics of Pathophysiology, Biomarkers, New therapeutic approaches, Drug delivery systems and Immuno-oncology and the tumor microenvironment.



[mdpi.com/si/157067](https://mdpi.com/si/157067)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)